The Latest Analyst Ratings for Vertex Pharmaceuticals
Portfolio Pulse from Benzinga Insights
The latest analyst ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) show a generally bullish sentiment, with 15 out of 20 analysts rating the stock as bullish or somewhat bullish. The average price target is $374.75, slightly above the current price of $371.0, implying an upside. This average price target has increased by 3.54% over the past month.
October 16, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analyst ratings for Vertex Pharmaceuticals are generally bullish, with an average price target slightly above the current price, implying an upside.
The bullish sentiment from analysts, along with an average price target above the current price, suggests a potential upside for Vertex Pharmaceuticals' stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100